Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), which is considered a promising target for ovarian cancer prevention and treatment.
The vaccine, being developed in collaboration with Cleveland Clinic and the National Cancer Institute, represents a novel approach particularly focused on high-risk populations, including individuals with BRCA mutations or family history of ovarian cancer. The allowed claims specifically cover methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide's extracellular domain to elicit an AMHR2-specific immune response.
Anixa Biosciences (NASDAQ: ANIX) ha ricevuto un Avviso di Concessione dall'USPTO per una domanda di brevetto chiave che copre la sua tecnologia per il vaccino contro il cancro ovarico. Il brevetto include ampie rivendicazioni relative a metodi per suscitare una risposta immunitaria mirata al recettore dell'ormone anti-Mulleriano, di tipo II (AMHR2), che è considerato un obiettivo promettente per la prevenzione e il trattamento del cancro ovarico.
Il vaccino, sviluppato in collaborazione con la Cleveland Clinic e il National Cancer Institute, rappresenta un approccio innovativo particolarmente focalizzato su popolazioni ad alto rischio, inclusi individui con mutazioni BRCA o storia familiare di cancro ovarico. Le rivendicazioni concesse coprono specificamente metodi per somministrare una composizione immunogenica contenente un acido nucleico che codifica il dominio extracellulare del polipeptide AMHR2 per suscitare una risposta immunitaria specifica per AMHR2.
Anixa Biosciences (NASDAQ: ANIX) ha recibido un Aviso de Concesión de la USPTO para una solicitud de patente clave que cubre su tecnología de vacuna contra el cáncer de ovario. La patente incluye amplias reivindicaciones relacionadas con métodos para provocar una respuesta inmunitaria dirigida al Receptor de Hormona Anti-Mulleriana, Tipo II (AMHR2), que se considera un objetivo prometedor para la prevención y el tratamiento del cáncer de ovario.
La vacuna, que se desarrolla en colaboración con la Cleveland Clinic y el National Cancer Institute, representa un enfoque novedoso particularmente enfocado en poblaciones de alto riesgo, incluidos individuos con mutaciones BRCA o antecedentes familiares de cáncer de ovario. Las reivindicaciones permitidas cubren específicamente métodos para administrar una composición inmunogénica que comprende un ácido nucleico que codifica el dominio extracelular del polipéptido AMHR2 para provocar una respuesta inmunitaria específica contra AMHR2.
Anixa Biosciences (NASDAQ: ANIX)는 자사의 난소암 백신 기술을 다룬 주요 특허 출원에 대해 USPTO로부터 허가 통지를 받았습니다. 이 특허는 항 뮬러 호르몬 수용체 II형(AMHR2)을 겨냥한 면역 반응을 유도하는 방법과 관련된 광범위한 청구를 포함하고 있으며, 이는 난소암 예방 및 치료를 위한 유망한 표적으로 간주됩니다.
이 백신은 Cleveland Clinic 및 National Cancer Institute와 협력하여 개발되고 있으며, BRCA 변이 또는 난소암 가족력이 있는 고위험 집단에 특히 초점을 맞춘 새로운 접근 방식을 나타냅니다. 허용된 청구는 AMHR2 특이적 면역 반응을 유도하기 위해 AMHR2 폴리펩타이드의 세포외 도메인을 인코딩하는 핵산을 포함하는 면역원성 조성물을 투여하는 방법을 구체적으로 다룹니다.
Anixa Biosciences (NASDAQ: ANIX) a reçu un Avis de Concession de l'USPTO pour une demande de brevet clé couvrant sa technologie de vaccin contre le cancer de l'ovaire. Le brevet comprend des revendications larges relatives aux méthodes d'induction d'une réponse immunitaire ciblant le Récepteur de l'Hormone Anti-Müllérienne, Type II (AMHR2), qui est considéré comme une cible prometteuse pour la prévention et le traitement du cancer de l'ovaire.
Le vaccin, développé en collaboration avec la Cleveland Clinic et le National Cancer Institute, représente une approche novatrice particulièrement axée sur les populations à haut risque, y compris les individus porteurs de mutations BRCA ou ayant des antécédents familiaux de cancer de l'ovaire. Les revendications autorisées couvrent spécifiquement les méthodes d'administration d'une composition immunogène comprenant un acide nucléique codant le domaine extracellulaire du polypeptide AMHR2 pour induire une réponse immunitaire spécifique à AMHR2.
Anixa Biosciences (NASDAQ: ANIX) hat einen Zulassungsbescheid vom USPTO für einen wichtigen Patentantrag erhalten, der seine Technologie für einen Impfstoff gegen Eierstockkrebs abdeckt. Das Patent umfasst umfassende Ansprüche zu Methoden zur Auslösung einer Immunantwort, die auf den Anti-Müller-Hormon-Rezeptor, Typ II (AMHR2) abzielt, der als vielversprechendes Ziel für die Prävention und Behandlung von Eierstockkrebs gilt.
Der Impfstoff, der in Zusammenarbeit mit der Cleveland Clinic und dem National Cancer Institute entwickelt wird, stellt einen neuartigen Ansatz dar, der sich insbesondere auf Hochrisikopopulationen konzentriert, einschließlich Personen mit BRCA-Mutationen oder einer familiären Vorgeschichte von Eierstockkrebs. Die zugelassenen Ansprüche decken spezifisch Methoden ab, um eine immunogene Zusammensetzung, die eine Nukleinsäure enthält, die die extrazelluläre Domäne des AMHR2-Polypeptids kodiert, zu verabreichen, um eine AMHR2-spezifische Immunantwort auszulösen.
- Secured USPTO Notice of Allowance for key ovarian cancer vaccine patent
- Patent provides broad protection for vaccine technology components and delivery mechanisms
- Strengthened intellectual property position in ovarian cancer prevention and treatment
- None.
Anixa's ovarian cancer vaccine, being developed in collaboration with Cleveland Clinic and the National Cancer Institute, represents a novel approach to preventing and treating ovarian cancer, particularly among high-risk populations such as those carrying BRCA mutations or with a family history of the disease.
The allowed claims include methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide, specifically the extracellular domain of human AMHR2, to elicit an AMHR2-specific immune response.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, commented, "Receiving this Notice of Allowance from the USPTO is a significant milestone in our mission to develop a preventative and therapeutic ovarian cancer vaccine. The allowed claims provide broad protection for the various components and delivery mechanisms of our vaccine technology. This strengthens our intellectual property position and supports the continued advancement of our program."
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-receives-notice-of-allowance-from-uspto-for-ovarian-cancer-vaccine-302408680.html
SOURCE Anixa Biosciences, Inc.
FAQ
What patent protection did Anixa Biosciences (ANIX) receive for its ovarian cancer vaccine?
Who are the development partners for Anixa's (ANIX) ovarian cancer vaccine?
What is the target population for Anixa's (ANIX) ovarian cancer vaccine?
What is the specific mechanism of Anixa's (ANIX) ovarian cancer vaccine?
